The first-in-class DOT1L inhibitor Pinometostat (EPZ-5676) provided proof-of-concept: treatment led to reduced H3K79 methylation and downregulation of HOX/MEIS1 expression in MLL-rearranged leukemia [50]. Here, KMT2A is linked to leukemia.